BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting 08 September
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism 06 September
